We are live on ! Find out more
SWTX

SpringWorks Therapeutics
SWTX

Delisted

SWTX was delisted on the 30th of June, 2025.

Back to rankings

44 hedge funds and large institutions have $681M invested in SpringWorks Therapeutics in 2019 Q3 according to their latest regulatory filings, with 44 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

72.34% more ownership

Funds ownership: 0% → 72.34% (+72%)

Holders
44
Holders Change
+44
Holders Change %
–
% of All Funds
0.96%
Holding in Top 10
5
Holding in Top 10 Change
+5
Holding in Top 10 Change %
% of All Funds
0.11%
New
44
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$175M
2
BCLSI
Bain Capital Life Sciences Investors
Massachusetts
+$172M
3
PA
Perceptive Advisors
New York
+$76.1M
4
BI
BVF Inc
California
+$67.2M
5
BC
Boxer Capital
California
+$49.1M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Wellington Management Group
26
Wellington Management Group
Massachusetts
$1.53M +$1.67M +70,577 New
Vanguard Group
27
Vanguard Group
Pennsylvania
$1.52M +$1.65M +70,000 New
Goldman Sachs
28
Goldman Sachs
New York
$1.1M +$1.2M +50,760 New
PPA
29
Parametric Portfolio Associates
Washington
$878K +$958K +40,514 New
MWNA
30
Marshall Wace North America
New York
$775K +$845K +35,761 New
CS
31
Credit Suisse
Switzerland
$592K +$646K +27,319 New
DIM
32
DC Investments Management
Virginia
$575K +$627K +26,513 New
Northern Trust
33
Northern Trust
Illinois
$393K +$428K +18,124 New
WAM
34
Weiss Asset Management
Massachusetts
$373K +$406K +17,194 New
Susquehanna International Group
35
Susquehanna International Group
Pennsylvania
$312K +$340K +14,392 New
Jane Street
36
Jane Street
New York
$307K +$334K +14,142 New
DKCM
37
Davidson Kempner Capital Management
New York
$271K +$295K +12,500 New
Tudor Investment Corp
38
Tudor Investment Corp
Connecticut
$223K +$243K +10,276 New
Morgan Stanley
39
Morgan Stanley
New York
$139K +$152K +6,432 New
UBS Group
40
UBS Group
Switzerland
$51K +$55.4K +2,344 New
TRCT
41
Tower Research Capital (TRC)
New York
$22K +$24K +1,014 New
Wells Fargo
42
Wells Fargo
California
$9K +$9.46K +400 New
CCA
43
Catalyst Capital Advisors
New York
$6K +$6.15K +260 New
Legal & General Group
44
Legal & General Group
United Kingdom
$4K +$4.61K +195 New
1
2

SWTX Hedge Fund Activity: Q3 2019 in Review

44 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in SpringWorks Therapeutics (SWTX) for Q3 2019, worth a combined $681M.

Buyers outnumbered sellers: 44 funds opened new SWTX positions and 0 closed out — a net gain of 44 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $175M.

  • 44 institutional investors held SpringWorks Therapeutics (SWTX) as of Q3 2019, up from 0 in Q2 2019.
  • Funds reported $681M of SpringWorks Therapeutics stock for Q3 2019.
  • 44 funds opened new SpringWorks Therapeutics positions in Q3 2019 and 0 closed out, a net change of +44 holders.
  • The largest SpringWorks Therapeutics buyer in Q3 2019 was OrbiMed, an estimated $175M added.

Based on aggregated 13F filings for Q3 2019.